Drug Transporter (DT) Information

General Information of DT
DT ID DTD0001
Gene Name ABCC1
Protein Name Multidrug resistance-associated protein 1
Gene ID
4363
UniProt ID
P33527
TCDB ID
3.A.1.208.8
3D Structure

Modelled DT Structure

Method: homology modeling

Template PDB: 6UY0_A

Identity: 90.725%

Minimized Score: -3891.081 kcal/mol

Detail: Structure Info

Synonyms ABC29; ABCC; ABCC1; ATP-binding cassette sub-family C member 1; GS-X; LTC4 transporter; Leukotriene C(4) transporter; MRP; MRP1
DT Family ATP-Binding Cassette (ABC) Superfamily
Drug Conjugate Transporter (DCT) Family (ABCC)
Tissue Specificity High expressed in testis, cardiomyocytes, placenta, prostate, lung, thymus, and kidney, lower expression in small intestine, colon, brain, and mononuclear cells
Function This transporter mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Disease(s) Acute myeloid leukemia [ICD-11: 2A60]
High blood pressure [ICD-11: BA00]
Human immunodeficiency virus infection [ICD-11: 1C62.Z]
Strongyloidiasis due to nematode parasite [ICD-11: 1F6B]
Kaposi's sarcoma [ICD-11: 2B57]
Ovarian cancer [ICD-11: 2C73]
Type 2 diabetes [ICD-11: 5A11]
Seizures following neurosurgery [ICD-11: 8A6Z]
Urticaria [ICD-11: EB00-EB0Y]
Node-positive breast cancer [ICD-11: 2C60-2C6Z]
Endogenous Substrate(s) Antimonial oxyanions; Antimony; Arsenic oxyanions; Arsenic triglutathione; Glutathione conjugates; Mercuric ions; Arsenate; Glucuronide-X; Aflatoxin B1-glutathione; Cobalamine; Leukotriene C4
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

Structural Variability Data of This DT (VARIDT 2.0)

(α) Mutation-induced Structural Variation
Mutation-induced Structural Variation (MSV)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

(γ) Outward/inward-facing Conformation
Outward/inward-facing Conformation (OIC)

(δ) Xenobiotics-regulated Structural Variability
Xenobiotics-regulated Structural Variability (XSV)

General Variability Data of This DT (VARIDT 1.0)

(α) Genetic Polymorphisms of This DT
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:          37 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
99mTc-sestamibi
 Approved Drug Info Breast cancer 2C60-2C6Z [1]
Adefovir
 Approved Drug Info Herpes simplex virus infection 1F00 [2]
Cefadroxil
 Approved Drug Info Gram-positive & negative bacteria infections 1A00-1H0Z [3]
Chlorpheniramine
 Approved Drug Info Urticaria EB00-EB0Y [4]
Cisplatin
 Approved Drug Info Testicular cancer 2C80 [5]
Citalopram
 Approved Drug Info Depression 6A8Z [6]
Colchicine
 Approved Drug Info Acute gouty arthritis FA25 [7]
Dactinomycin
 Approved Drug Info Cancer 2A00-2F9Z [8]
Daunorubicin
 Approved Drug Info Acute myeloid leukemia 2A60 [9]
Dehydroepiandrosterone sulfate
 Approved Drug Info Dyspareunia GA12 [10]
Docetaxel
 Approved Drug Info Lung cancer 2C25 [2]
Doxorubicin
 Approved Drug Info Leukemia 2A60-2B33 [11]
Epirubicin
 Approved Drug Info Node-positive breast cancer 2C60-2C6Z [12]
Estrone sulfate
 Approved Drug Info Menopausal symptoms MF32 [13]
Ethacrynic acid
 Approved Drug Info High blood pressure BA00 [14]
Etoposide
 Approved Drug Info Testicular cancer 2C80 [15]
Fluorescein
 Approved Drug Info Ocular disease 9E1Z [16]
Flutamide
 Approved Drug Info Prostate cancer 2C82 [17]
Folic acid
 Approved Drug Info Vitamin deficiency 5B55-5B7Z [18]
Glutathione
 Approved Drug Info Human immunodeficiency virus infection 1C62.Z [19]
Grepafloxacin
 Approved Drug Info Chronic bronchitis CA20.1 [20]
Idarubicin
 Approved Drug Info Acute myeloid leukemia 2A60 [2]
Indinavir
 Approved Drug Info Human immunodeficiency virus infection 1C62.Z [2]
Irinotecan
 Approved Drug Info Colorectal cancer 2B91 [21]
Ivermectin
 Approved Drug Info Strongyloidiasis due to nematode parasite 1F6B [22]
Lopinavir
 Approved Drug Info Human immunodeficiency virus infection 1C62.Z [23]
Methotrexate
 Approved Drug Info Leukemia 2A60-2B33 [24]
Mitoxantrone
 Approved Drug Info Metastatic breast cancer 2C6Y [25]
Paclitaxel
 Approved Drug Info Breast cancer 2C60-2C6Z [2]
Phenytoin
 Approved Drug Info Seizures following neurosurgery 8A6Z [26]
Saquinavir
 Approved Drug Info Human immunodeficiency virus infection 1C62.Z [27]
Saxagliptin
 Approved Drug Info Type 2 diabetes 5A11 [28]
Topotecan
 Approved Drug Info Ovarian cancer 2C73 [2]
Verapamil
 Approved Drug Info High blood pressure BA00 [2]
Vinblastine
 Approved Drug Info Testicular cancer 2C80 [29]
Vincristine
 Approved Drug Info Acute lymphoblastic leukemia 2B33.0 [30]
Zoledronic acid
 Approved Drug Info Paget's disease FB85 [31]

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:            4 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Phenethyl isothiocyanate
 Phase 3 Drug Info Cancer 2A00-2F9Z [2]
Glutathione-S-S-glutathione
 Phase 2 Drug Info Ovarian cancer 2C73 [32]
SN-38
 Phase 2 Drug Info Colon cancer 2B90.Z [21]
Chlorcyclizine
 Phase 1 Drug Info Hepatitis C virus infection 1E50.2, 1E51.1 [4]

 Phase 3 Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Quercetin
 Phase 3 Drug Info Coronary artery disease BA6Z [2]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            3 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Aminohippuric acid
 Withdrawn Drug Info Renal function tests MG02 [33]
Resveratrol
 Discontinued in Phase 2 Drug Info Colorectal cancer 2B91 [2]
Leukotriene E4
 Preclinical Drug Info Asthma CA23 [34]

Endogenous Metabolites (EMs) Handled by This DT

 Endogenous Metabolites (EMs)

 Click to Show/Hide the Full List of EMs:            1 EMs in Total
EM Name PubChem CID Detail Experimental Material Ref
Guanidine
3520
EM Info Identified using MATE1-overexpressing HEK293 cells [35]

Drug-DT Affinity Assessed by Cell Line

 Approved Drug

 Click to Show/Hide the Full List of Drug:          11 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Cefadroxil Approved Drug Info Human embryonic kidney cells (HEK293)-MRP1 Km = 3.9 microM [3]
Citalopram Approved Drug Info Human embryonic kidney cells (HEK293)-MRP1 Km = 1.99 microM [6]
Daunorubicin Approved Drug Info Human small cell lung cancer cells Km = 1.4 microM [36]
Epirubicin Approved Drug Info Human cervical cancer cell line (Hela)-MRP1 Km = 0.097 microM [12]
Estrone sulfate Approved Drug Info Human cervical cancer cell line (Hela)-MRP1 Km = 0.73 microM [37]
Estrone sulfate Approved Drug Info Human cervical cancer cell line (Hela)-MRP1 Km = 2.1 microM [37]
Estrone sulfate Approved Drug Info Human embryonic kidney cells (HEK293)-MRP1 Km = 4.2 microM [13]
Glutathione Approved Drug Info Human cervical cancer cell line (Hela)-MRP1 Km = 5000 microM [38]
Methotrexate Approved Drug Info Breast carcinoma cell line (MCF7)-MRP1 Km = 930 microM [39]
Methotrexate Approved Drug Info Human embryonic kidney cells (HEK293)-MRP1 Km = 2150 microM [24]
Methotrexate Approved Drug Info NIH3T3-MRP1 Km = 2150 microM [24]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            5 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Aminohippuric acid Withdrawn Drug Info Human cervical cancer cell line (Hela)-MRP1 Km = 372 microM [33]
Estradiol-17beta-glucuronide Investigative Drug Info Human cervical cancer cell line (Hela)-MRP1 Km = 1.5 microM [34]
Estradiol-17beta-glucuronide Investigative Drug Info Human cervical cancer cell line (Hela)-MRP1 Km = 2.5 microM [40]
Estradiol-17beta-glucuronide Investigative Drug Info Human embryonic kidney cells (HEK293)-MRP1 Km = 1.5 microM [41]
Fluo-3 Investigative Drug Info Human cervical cancer cell line (Hela)-MRP1 Km = 12 microM [42]
References
1 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer. 1998;77(3):353-8.
2 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
3 Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
4 Carrier mediated transport of chlorpheniramine and chlorcyclizine across bovine olfactory mucosa: implications on nose-to-brain transport. J Pharm Sci. 2005 Mar;94(3):613-24.
5 Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
6 MRP1 polymorphisms associated with citalopram response in patients with major depression. J Clin Psychopharmacol. 2010 Apr;30(2):116-25.
7 Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol Pharmacol. 1997 Sep;52(3):344-53.
8 Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res. 1995 Nov 15;55(22):5342-7.
9 Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
10 Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7.
11 The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
12 Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion. J Biomed Res. 2016 Mar;30(2):120-133.
13 Molecular cloning and pharmacological characterization of rat multidrug resistance protein 1 (mrp1). Drug Metab Dispos. 2003 Aug;31(8):1016-26.
14 Inhibition of the multidrug resistance protein 1 (MRP1) by peptidomimetic glutathione-conjugate analogs. Mol Pharmacol. 2002 Nov;62(5):1160-6.
15 Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
16 Transport of fluorescein in MDCKII-MRP1 transfected cells and mrp1-knockout mice. Biochem Biophys Res Commun. 2001 Jun 22;284(4):863-9.
17 The multidrug resistance-associated protein 1 transports methoxychlor and protects the seminiferous epithelium from injury. Toxicol Lett. 2003 Apr 30;142(1-2):61-70.
18 Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
19 Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos. 2008 Dec;36(12):2571-81.
20 Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier. J Pharmacol Exp Ther. 2000 Oct;295(1):146-52.
21 ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
22 Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3). Chem Biol Interact. 2006 Feb 25;159(3):169-79.
23 Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother. 2007 Nov;60(5):987-93.
24 Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
25 Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol Pharmacol. 2006 Apr;69(4):1499-505.
26 Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology. 2010 Jun;58(7):1019-32.
27 Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother. 2002 Nov;46(11):3456-62.
28 Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet. 2010 Sep;49(9):573-88.
29 Development and characterization of a recombinant Madin-Darby canine kidney cell line that expresses rat multidrug resistance-associated protein 1 (rMRP1). AAPS PharmSci. 2004 Mar 9;6(1):E8.
30 Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur J Pharmacol. 2008 Sep 4;591(1-3):128-31.
31 Zoledronic acid is synergic with vinblastine to induce apoptosis in a multidrug resistance protein-1 dependent way: an in vitro study. Cell Biol Int. 2006 Mar;30(3):278-82.
32 Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Biochim Biophys Acta. 1997 May 22;1326(1):12-22.
33 ATP-dependent para-aminohippurate transport by apical multidrug resistance protein MRP2. Kidney Int. 2000 Apr;57(4):1636-42.
34 Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. 1996 Mar 1;56(5):988-94.
35 Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
36 Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells. Biochem Pharmacol. 1994 Sep 15;48(6):1129-36.
37 Glutathione stimulates sulfated estrogen transport by multidrug resistance protein 1. J Biol Chem. 2001 Mar 2;276(9):6404-11.
38 Topological polar surface area defines substrate transport by multidrug resistance associated protein 1 (MRP1/ABCC1). J Med Chem. 2009 Feb 26;52(4):1214-8.
39 Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells. Biochemistry. 2003 May 13;42(18):5429-37.
40 ATP-dependent 17 beta-estradiol 17-(beta-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. J Biol Chem. 1996 Apr 19;271(16):9683-9.
41 Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol. 1999 May;55(5):929-37.
42 Export pumps for anionic conjugates encoded by MRP genes. Adv Enzyme Regul. 1999;39:237-46.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.